腹腔镜手术与腹腔镜NOSE用于乙状结肠及直肠癌的安全性与疗效比较
本荟萃分析比较腹腔镜自然腔道标本取出术(La-NOSE)与传统腹腔镜(CL)在乙状结肠及直肠癌中的临床与肿瘤学安全性和疗效。结果显示La-NOSE组住院时间更短、术后第一天疼痛评分更低、围术期总并发症和手术部位感染发生率更低,吻合口漏及5年无病生存和总生存无显著差异。
要点
- La-NOSE组围术期总并发症(OR 0.46)和手术部位感染(OR 0.11)显著低于CL组。
- La-NOSE组住院时间和术后第一天疼痛评分均短于/低于CL组。
- 两组吻合口漏、5年无病生存和总生存无显著差异。
核心结论
- 对于乙状结肠及直肠癌患者,La-NOSE可达到与传统腹腔镜相当的肿瘤学与手术安全性。
- La-NOSE与更短住院时间、更短首次排气或排便时间、更轻术后疼痛、更少手术部位感染和围术期总并发症相关。
- La-NOSE手术时间通常长于传统腹腔镜,长期肿瘤学疗效似乎与传统腹腔镜等效。
研究设计与样本
- 荟萃分析,检索PubMed、Web of Science和Cochrane数据库,纳入比较La-NOSE与传统腹腔镜用于乙状结肠及直肠癌临床或肿瘤学结局的研究。
主要发现
- La-NOSE组围术期总并发症发生率低于CL组(OR 0.46;95% CI [0.32 to 0.66];I2 = 0%;P < 0.0001)。
- La-NOSE组手术部位感染发生率低于CL组(OR 0.11;95% CI [0.04 to 0.29];I2 = 0%;P < 0.0001)。
- 两组吻合口漏无显著差异(P = 0.19)。
- 两组5年无病生存(P = 0.43)和5年总生存(P = 0.40)无显著差异。
临床怎么用
- 在乙状结肠及直肠癌微创手术中,La-NOSE可作为传统腹腔镜的替代选择,需权衡较长手术时间与更短住院、更少并发症的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laparoscopic surgery with natural orifice specimen extraction (La-NOSE) is being performed more frequently for the minimally invasive management of sigmoid and rectal cancer. The objective of this meta-analysis was to compare the clinical and oncological safety and efficacy of La-NOSE versus conventional laparoscopy (CL). METHODS: A search of the PubMed, Web of Science, and Cochrane databases was performed for studies that compared clinical or oncological outcomes of conventional laparoscopic resection using NOSE with conventional laparoscopic resection for sigmoid and rectal cancer. RESULTS: Compared with CL group, the length of hospital stay and the pain score on the first day were shorter in the La-Nose group. The La-NOSE group had a lower incidence of total perioperative complications (OR 0.46; 95% CI [0.32 to 0.66]; I2 = 0%; P < 0.0001) and a lower incidence of surgical site infections (SSIs) (OR 0.11; 95% CI [0.04 to 0.29]; I2 = 0%; P < 0.0001) than the CL group, while the anastomotic leakage showed no significant difference between the La-Nose group and the CL group (P = 0.19). 5-year disease-free survival (DFS) and 5-year overall survival (OS) were no significant difference between the La-Nose group and the CL group (P = 0.43, P = 0.40, respectively). CONCLUSIONS: La-NOSE can achieve oncological and surgical safety comparable to that of CL for patients with sigmoid and rectal cancer. La-NOSE in patients was associated with a shorter hospital stay, shorter time to first flatus or defecation, less postoperative pain, and fewer surgical site infections (SSIs) and total perioperative complications. In general, the operative time in La-NOSE was longer than that in CL. The long-term oncological efficacy of La-NOSE seems to be equivalent to that of CL.
引用
- Xu S, Liu K, Chen X, et al. The safety and efficacy of laparoscopic surgery versus laparoscopic NOSE for sigmoid and rectal cancer. Surg Endosc. 2021. PMID: 33475847. doi:10.1007/s00464-020-08260-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。